

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Piero DEL SOLDATO et al.

Attorney Docket Number: 026220-00048

Serial Number: NEW PATENT APPLICATION

Filed: July 23, 2004

For: NEW CORTICOSTEROIDS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Date: July 23, 2004


Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information items listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each item is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the items be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date, OR (b) before the mailing date of a first Office Action on the merits in the present application, OR (c) accompanies a Request for Continued Examination. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

- ☐ c. Check number _____ in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account Number 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicants hereby petition that the Information Disclosure Statement be considered. Attached is our check number _____ in the amount of \$180.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account Number 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

Respectfully submitted,


Richard J. Berman
Registration Number 39,107

Customer Number 004372
ARENT FOX PLLC
1050 Connecticut Avenue, NW
Suite 400
Washington, DC 20036-5339
Telephone: (202) 857-6000
Fax: (202) 638-4810

RJB:vmh

Enclosures: Form PTO-1449
International Search Report
References (11)

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NUMBER 026220-00048	NEW PATENT APPLICATION
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Piero DEL SOLDATO et al.	
		FILING DATE July 23, 2004	GROUP ART UNIT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO PART.		
	AC	EP 1 336 602 A1	August 20, 2003	Europe			X		
	AD	1 037 451	August 28, 1958	Germany				X	
	AE	WO 97/34871	September 25, 1997	International			X		
	AF	WO 97/41144	November 6, 1997	International			X		
	AG	WO 98/15568	April 16, 1998	International			X		
	AH	WO 00/61604	October 19, 2000	International			X		
	AI	WO 02/051385 A1	July 4, 2002	International			X		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	JENSEN, Ejvind et al., "N-Substituted (Aminomethyl)Benzoate 21-Esters of Corticosteroids as Water-soluble, Solution-stable and Biolabile Prodrugs", XP-002249867, Correspondence, 1992, pages 35 – 42
	AK	KEEBLE, J. et al., "Vasorelaxant Effect of Nitric Oxide Releasing Steroidal and Nonsteroidal Anti-inflammatory Drugs", XP-001088994, British Journal of Pharmacology (2001) 133, pages 1023 – 1028
	AL	PAUL-CLARK, Mark et al., "21-NO-Prednisolone is a Novel Nitric Oxide-releasing Derivative of Prednisolone with Enhanced Anti-inflammatory Properties", XP-001088964, British Journal of Pharmacology (2000) 131, pages 1345 – 1354
	AM	TALLET, Dominique et al., "NO-Steroids: Potent Anti-inflammatory Drugs with Bronchodilating Activity <i>in Vitro</i> ", XP-002210203, Biochemical and Biophysical Research Communications 290 (2002), pages 125 – 130

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	